Kevin (@BiochemKev) header
Kevin (@BiochemKev) profile picture

UBC PhD Candidate in Pharmaceutical Science Building next gen LNP-RNA w/ biomimetic design Beating the market w/ commercial stage biotechs

Vancouver, BC
Joined February 2021
Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)Photo by Kevin (@BiochemKev)
Kevin retweeted
$PRME Danaher just put prime editing and base editing on the shelf. IDT + Aldevron, Nov 4:
 • PE Ultra prime editor mRNA, chemically modified Alt-R pegRNAs, and a pegRNA design tool
 • Six stocked ABE8e base editors, plus a kit to screen all six at once
 • 20 µg to 1 mg in stock, larger runs custom Research grade. No CGMP timeline announced. What it replaces: sourcing a plasmid, making your own mRNA, and working out guide design by trial and error. Stocked inventory is a forecast. Danaher builds those with a spreadsheet, not a press release. Same two companies manufactured the components for the world's first mRNA-based personalized CRISPR therapy. Every target proven in an animal needs a human therapeutic license to go further.
2
4
20
2,312
Arrowhead Pharmaceuticals ($ARWR) is the weirdest company in the world. 🧬 In 2011, they bought a $1 billion tech portfolio for "pennies" while drinking pints in a London pub. Now, they are silencing genes to save lives. Here is the story of the ultimate Biotech Renaissance. 🧵 #BioTech #ARWR #Investing #Genomics 1/11
4
10
3
46
9,945
From Stifel: top 15 pub traded RNA therapeutics companies
8
20
115
14,070
4/ Yesterday Capstan Broke the Trend AbbVie paid $2.1B for Capstan’s in-vivo CAR-T at Phase 1. That’s 10–15x the typical single-asset price tag. Why? Because Capstan isn’t a product. It’s a platform. fiercebiotech.com/biotech/ab…
2
2
3
19
7,480
Dr. Pieter Cullis is changing the world, one tiny lipid nanoparticle at a time! cihr-irsc.gc.ca/e/54321.html…
13
30
2,859
Interesting comments on extrahepatic targeting of LNPs from a pioneer in the field.
𝐅𝐫𝐨𝐦 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫: Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery. Full video: biotechtv.com/post/nanovatio…
1
1
27
8,166
$ARWR some preclinical results of ARO-ALK7 (silencing with #Tirzepatide from $LLY). Investors need patience, but the opportunities for the #RNAi play in the obesity market are great in the long term. ir.arrowheadpharma.com/stati…
4
1
35
2,709
$ARWR: I bought $ARWR because I wanted more late stage companies with multiple drugs and multiple indications that could offer a lot of potential. I bought because the valuation was way below my estimates I bought because they have 2 later stage programs in cholesterol which are very competitive spaces. I am hopeful they can compete with other therapies in this space. I bought because they have 2 early obesity programs that could be huge if they are successful. They offer the option of the upside at a much better valuation than other companies in this space that are over hyped. I bought because they seem to have a sound management team and a good balance sheet. I bought because I can buy more cheaper if the sector crashes, but I could also sell for big profits if the sector rallies. I like that I am not married to the company so I can be flexible if my strategy changes.
1
2
1
16
2,919
Big opportunity for a Duchenne gene therapy that actually works!
$SRPT CEO says demand for their gene therapy is overwhelming. Haven’t even dosed 5% of eligible patients.
14
5
108
33,560
So wonderful to see Tim Harris’ book on biotech arrive from Amazon today! This is a MUST read for anyone interested in the history of biotech! Enjoy!!!
6
7
1
69
4,881
I have no doubt $IONS is pissed that they only received the smaller label (genetic FCS) with a max of 3k patients. If they don't run a ph3 for clinical FCS then they're basically admitting $ARWR is superior. #GameOver
4
3
49
4,841
The saga is finally over for $SAVA.
8
86
9,376
$TGTX MW has 2 targets 1. $6B mc $40.16 ps for 1.08M share bonus in 2024 2. $10B mc approx $70 ps for $16.7M bonus by 2026 On top of the 12M shares he currently owns, can see why he hasn’t raised and would “personally finance TGTX if needed”
1st image: When a biotech CSO gets 81k in relocation assistance (?) 2nd image: Imagine waiting for TGTX to hit $40.16 and it hits high of $35. I'd be nervous!
3
5
23
1,995
There have been vague whispers of bid interest for $TGTX from AstraZeneca, GSK and Novartis although the hot money is on a move from Roche at upwards of $60 a share. Banks including JP Morgan and Goldman Sachs are rumoured to be involved....
26
14
13
75
98,734
FACT OR FICTION? LNP DELIVERY BEYOND LIVER Has the biotech world quietly solved one of the biggest limitations of LNPs? Is delivery beyond the liver ready for prime time? Like if true; comment if false
7
7
44
9,456
From Peter Cullis ("Father of LNP") - wrote an awesome review on reflecting history of LNP development nature.com/articles/s41573-0…
1
2
10
1,188
Our 2024 Annual Meeting & Exposition Starts Today! At #CRS2024, we look forward to another exciting and innovative event where we celebrate delivery science and technology by sharing scientific knowledge and learning new technologies with colleagues from around the world.
13
1
38
3,266
#CRISPR I attended #CRISPRmedicine24, so you don't have to :) My key take-homes (uncontroversial conference consensus): 1) off-targeting, off-targeting...not solved 2) base editing with less off-targeting, but translocations and on-target indels surprisingly prevalent; no grip on assessing gRNA-independent base editing 3) great progress in HDR (homologous recombination) with efficiencies in 60%+ in presence of NHEJ inhibitors; drawback: increase in translocations 4) enormous focus on HSC-based applications (or do HSC people just speak the loudest?) 5) delivery: adoption of small Cas proteins 6) regulatory advice: focus on unmet medical needs to justify intervention $NTLA $BEAM $PRME $CRSP
4
3
1
45
11,761